CA-ARIA-SYSTEMS
9.8.2022 13:02:07 CEST | Business Wire | Press release
Aria Systems , the leader in helping enterprises grow subscription and usage-based revenue, today announced the company will be at Digital Transformation World (DTW) in September to present the findings and solution resulting from its involvement in one of TM Forum’s most championed catalyst programs. Aria and its partners have been exploring how an event-driven architecture can enable service providers to build more scalable and flexible IT architecture with lower integration costs, and faster time to market.
Catalysts are proof-of-concept projects developed collaboratively by members to solve problems presented by leading global communications service providers (CSPs) and define and propose new industry standards. Together with its partners and CSP champions, Aria will demonstrate how the Open Digital Framework (ODF) can be enhanced for organizations that have adopted a modern event-driven architecture.
“As CSPs transform their BSS solution with best-of-breed capabilities to support new opportunities delivered by software-defined networks, zero-touch automation, and cloud partnerships, their ecosystems grow in complexity,” said Brendan O’Brien, Aria Co-founder and Chief Innovation Officer. “While the TM Forum Open API and ODA standards have helped ease integration burdens, loosely coupled event-based architectures, such as those adopted by the internet industry, are proving more nimble and scalable. The catalyst team at DTW will demonstrate how existing TM Forum APIs can be enhanced for an event-based architecture with additional standardized patterns to ensure robustness and assurance in service delivery, orchestration, and monetization.”
In April, Aria became a founding participant in the catalyst entitled “Async Open APIs for Event-Based Architectures,” championed by BT, Jio, Orange, Telenor, Verizon, Vodafone, and lead champion CityFibre. Aria has been working alongside CPQ vendor Bit2win and systems integrators EPAM, TechMahindra, and Yupiik to demonstrate how, as operators move from large BSS/OSS systems to a best-of-breed ODA framework, open APIs can be converted and extended to support an event-based architecture, enabling greater flexibility and faster time to market for dynamic and growing ecosystems and partnerships.
“In addition to meeting the specific challenges posed by our CSP champions, the results of the catalyst also demonstrate how Aria’s open architecture philosophy natively supports this technical transformation journey, delivering significant impact and benefits in terms of speed and cost,” O’Brien continued.
Aria will present the results of the catalyst alongside partners during a theater presentation at DTW, taking place in Copenhagen from September 20-22. The company will also demonstrate the solution in the TM Forum catalyst booth and at its DTW booth (#304).
About Aria Systems:
Aria Systems’ native public cloud monetization platform is the analysts’ choice, top ranked by leading research firms. Innovative enterprises like Adobe, Comcast, Liberty Latin America, Subaru, and Telstra depend on Aria to accelerate time to market and increase flexibility, enabling them to maximize customer value, and grow recurring revenue through subscription, usage-based, and one-time offerings. For more information, visit: www.ariasystems.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220809005073/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom